Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Esophageal Adenocarcinoma · Gastric Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Contact: Principal Investigator (Nataliya Uboha, MD, PhD)
Study leads
Nataliya Uboha, MD, PhD
Principal Investigator
University of Wisconsin, Madison